The E-SUPeR study extends the follow-up of women in the SUPeR clinical trial up to 10 years from the time of surgery. The primary aim of SUPeR was to determine whether treatment success in women with symptomatic uterovaginal prolapse undergoing transvaginal mesh augmented hysteropexy differs in women undergoing vaginal hysterectomy and native tissue cuff suspension at time points through 3 years. The SUPeR participant population represents a unique opportunity to understand the longer term efficacy and safety outcomes of a native tissue repair and a mesh hysteropexy. Participants will be seen annually for a physical exam and will be asked to complete a reduced set questionnaires (PFDI-20, PFIQ, PGI-I, ISI, and PISQ-IR.)